Two endogenous antiangiogenic inhibitors, endostatin and angiostatin, demonstrate biphasic curves in their antitumor profiles

Dose-Response

Volumn 9, Issue 3, 2011, Pages 369-376

  Javaherian, Kashi ^a   Lee, Tong Young ^b   Sjin, Robert M Tjin Tham ^b   Parris, George E ^a   Hlatky, Lynn ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Angiostatin; Biphasic; Endostatin

Indexed keywords

AFLIBERCEPT; ANGIOSTATIN; BEVACIZUMAB; ENDOSTATIN; RECOMBINANT ENDOSTATIN; RECOMBINANT FC ENDOSTATIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; DRUG HALF LIFE; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; LUNG CANCER; MELANOMA; NONHUMAN; OPTIMAL DRUG DOSE; PANCREAS TUMOR; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN TARGETING; RECTUM CANCER; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 80054700304     PISSN: None     EISSN: 15593258     Source Type: Journal    
DOI: 10.2203/dose-response.10-020.Javaherian     Document Type: Article

References (17)

1. Abdollahi A, Hlatky L, Huber PE. 2005. Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 8: 59-74.
2. Celik I, Surucu O, Dietz C, Heymach JV, Force J, Hoschele I, Becker CM, Folkman J, Kisker O. 2005. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65: 11044-11050.
3. Conolly RB, Lutz WK. 2004. Nonmonotonic dose-response relationship: mechanistic basis, kinetic modeling, and implications for risk assessment. Toxicol Sci 77(2): 151-157.
4. Ding YH, Javaherian k, Lo K-M, Chopra R, Boehm T, Lanciotti J, Harris BA, Li YL, Shapiro R, Hohenester E, Timpl R, Folkman J, Wiley, D. 1998. Zinc-dependent dimers observed in crystals of human endostatin. Proc Natl Acad Sci U S A 95: 10443-10448.
5. Folkman J. 2006. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312: 594-607.
6. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. 1990. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 87: 6624-6628.
7. Lee TY, Muschal S, Pravda EA, Folkman J, Abdollahi A, Javaherian K. 2009. Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood 114: 1987-1998.
8. Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda EA, Lo KM, Gillies SD, Folkman J, Javaherian K. 2008. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 14: 1487-1493.
9. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV. 1999. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 96: 2811-2816.
10. Motegi K, Harada K, Pazouki S, Baillie R, Schor AM. 2002. Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis. Histochem J 34: 411-421.
11. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
12. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
13. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahenfeldt P, Folkman J, Kaipainen A. 2002. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110: 923-932.
14. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. 1999. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5: 2726-2734.
15. Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, Ramanujam VMS, Folkman J, Javaherian K. 2005. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 65: 3656-3663.
16. Tjin Tham Sjin RM, Naspinski J, Birsner AE, Li C, Chan R, Lo K-M, Gillies S, Zurakowski D, Folkman J, Samulski J, Javaherian K. 2006. Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther 13: 619-627.
17. Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV. 2005. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem 96: 242-261.